tuberculosi
tb
remain
seriou
health
problem
worldwid
onethird
popul
infect
mycobacterium
tuberculosi
mtb
peopl
infect
dormant
mtb
diagnos
nonclin
tb
latent
tb
infect
peopl
develop
tb
diseas
live
furthermor
latent
infect
individu
year
risk
develop
activ
tb
diseas
hivinfect
person
receiv
antiretrovir
therapi
cohn
therefor
success
vaccin
mtb
infect
need
mycobacterium
bovi
bacillu
bcg
avail
vaccin
tb
fail
control
adult
tb
establish
latent
persist
tb
infect
brewer
glyn
hewinson
accord
previou
studi
cellmedi
immun
character
secret
cytokin
play
import
role
protect
mtb
infect
cooper
vaccinespecif
cell
memori
also
confer
protect
upon
secondari
challeng
qualit
differ
quantit
enhanc
respons
henaotamayo
et
al
previous
show
novel
tripleantigen
fusion
dna
vaccin
engin
three
welldefin
mycobacteri
antigen
millington
et
al
hogarth
et
al
bett
et
al
induc
robust
cellmedi
immun
respons
follow
four
immun
kong
et
al
consid
mani
issu
area
lack
medic
infrastructur
support
multipl
inject
fachado
et
al
vaccin
needlefre
singl
dose
consid
import
goal
vaccin
develop
vesicular
stomat
viru
vsv
negativestrand
rna
viru
prove
favorit
viral
vector
deliveri
foreign
vaccin
antigen
rose
et
al
haglund
et
al
clark
et
al
braxton
et
al
vsv
three
major
advantag
potenti
deliveri
platform
tb
first
group
demonstr
vsv
vaccin
mucosa
tan
et
al
wu
et
al
believ
superior
elicit
protect
immun
respons
infecti
diseas
site
infect
davi
second
help
vsv
revers
genet
system
addit
gene
easili
insert
viral
genom
recombin
vsv
rvsv
express
foreign
antigen
grown
high
titer
mammalian
cell
line
goonetillek
et
al
third
rvsv
could
stimul
potent
humor
cellmedi
immun
respons
needlefre
singl
dose
anim
model
johnson
et
al
faber
et
al
cobleigh
et
al
addit
preval
antivsv
antibodi
gener
popul
extrem
low
therefor
peopl
carri
preexist
antibodi
counteract
vsvbase
vaccin
lichti
et
al
previous
vsv
base
tb
vaccin
express
highli
immunogen
antigen
shown
protect
upon
pulmonari
mtb
challeng
administr
mice
intranas
roedig
et
al
howev
protect
manifest
earli
timepoint
detect
week
follow
immun
sustain
develop
vsvbase
vaccin
express
welldefin
tripleantigen
fusion
gene
effect
mycobacterium
infect
describ
previou
report
kong
et
al
result
indic
vaccin
elicit
remark
cellmedi
immun
respons
provid
effect
longterm
protect
follow
bcg
challeng
within
needlefre
singl
dose
find
may
also
provid
insight
mtbvaccin
develop
femal
balbc
mice
week
old
purchas
experiment
anim
center
chines
academi
scienc
maintain
pathogenfre
condit
anim
experi
perform
accord
laboratori
anim
guidelin
laboratori
anim
ethic
commiss
soochow
univers
mice
lightli
anesthet
isofluran
baxter
dilut
propylen
glycol
prior
immun
singl
intranas
inocul
pfu
administ
volum
bcg
immun
mice
receiv
singl
dose
colonyform
unit
cfu
bcg
subcutan
plasmid
immun
mice
intramuscularli
inject
time
biweekli
induc
immun
respons
protect
detect
group
consist
twelv
mice
six
mice
per
group
sacrif
week
final
dna
vaccin
releas
assay
lymphocyt
prolifer
assay
cytotox
lymphocyt
measument
six
mice
per
group
challeng
bcg
week
final
dna
vaccin
sacrif
week
challeng
bacteri
load
detect
induc
longterm
protect
detect
group
consist
eighteen
mice
six
mice
per
group
sacrif
week
bcg
challeng
bacteri
load
detect
evalu
patholog
induc
memori
cell
detect
group
consist
six
mice
mice
sacrif
week
final
dna
vaccin
memori
cell
detect
escherichia
coli
strain
grown
luriabertani
medium
clone
bovi
bcg
denmark
strain
provid
center
diseas
control
suzhou
cultiv
middlebrook
medium
enumer
agar
supplement
oleic
acidalbumindextrosecatalas
glycerol
tween
inactiv
mtb
strain
provid
fifth
peopl
hospit
suzhou
fusion
geneencod
amplifi
pcr
previous
describ
kong
et
al
pcr
product
cleav
xhoi
nhei
clone
fifth
posit
plasmid
cobleigh
et
al
gener
recombin
viru
gener
follow
procedur
brief
babi
hamster
kidney
cell
atcc
number
grown
confluenc
infect
recombin
vaccinia
viru
express
rna
polymeras
fuerst
et
al
incub
h
serumfre
dulbecco
modifi
eagl
medium
dmem
vaccinia
virusinfect
cell
cotransfect
plasmid
plasmid
express
vsv
n
p
l
ritz
et
al
supernat
collect
h
post
transfect
filter
pore
filter
remov
vaccinia
viru
passag
onto
fresh
cell
medium
collect
immedi
filter
pore
filter
cytopath
effect
observ
day
later
recombin
vsv
plaqu
purifi
expand
titer
determin
store
use
cell
infect
harvest
h
postinfect
cell
wash
phosphatebuff
salin
pb
lyse
sd
sampl
buffer
protein
separ
sd
gel
transfer
nitrocellulos
membran
probe
antiflag
antibodi
sigma
detect
secondari
antibodi
southern
biotech
use
chemiluminesc
two
week
last
immun
spleen
cell
isol
vaccineimmun
mice
plate
cellswel
plate
cell
stimul
protein
previous
describ
kong
et
al
h
concentr
cultur
supernat
measur
elisa
kit
ebiosci
accord
manufactur
procedur
prolifer
splenocyt
immun
mice
measur
week
last
immun
viabl
splenocyt
adjust
concentr
cellsml
ad
flatbottom
plate
cellswel
protein
brdulabel
reagent
roch
ad
well
ratio
cultur
plate
maintain
condit
anoth
h
incub
antibrdu
peroxidas
absorpt
valu
nm
measur
sampl
analyz
triplic
two
week
final
dna
immun
splenocyt
isol
stimul
vitro
recombin
protein
vaccin
mice
mous
myeloma
cell
line
cell
cell
bank
chines
academi
scienc
puls
inactiv
tb
h
target
cell
nonradioact
cytotox
lymphocyt
ctl
assay
perform
lactat
dehydrogenas
ldh
cytotox
detect
kit
roch
effector
cell
titrat
ubottom
plate
cell
ratio
target
cell
ad
incub
h
ul
cell
supernat
per
well
remov
transfer
correspond
well
plate
reaction
mixtur
ul
ad
well
incub
room
temperatur
min
absorb
valu
nm
measur
percentag
cytotox
ctl
calcul
follow
accord
protocol
high
control
maximum
releas
ldh
activ
cell
ul
cell
cultur
medium
ul
untreat
cell
ul
lysi
buffer
low
control
spontan
ldh
activ
releas
untreat
normal
cell
ul
cell
cultur
medium
ul
untreat
cell
six
week
final
dna
vaccin
immun
mice
intranas
challeng
cfu
bcg
previouli
describ
kong
et
al
song
et
al
bacteria
load
spleen
lung
indic
time
point
postchalleng
count
accord
colonyform
unit
serial
dilut
tissu
homogen
middlebrook
medium
triplic
histopatholog
analysi
lung
immun
mice
n
per
group
collect
week
post
bcg
challeng
tissu
section
stain
hematoxylin
eosin
five
section
made
mous
one
experi
two
section
mous
randomli
select
total
twelv
section
group
evalu
inflamm
score
two
independ
investig
one
experi
inflamm
score
assess
percentag
inflamm
area
compar
overal
size
tissu
section
aid
microscop
eyepiec
grid
previous
report
fairweath
et
al
liu
et
al
twenti
four
week
post
final
dna
immun
splenocyt
isol
immun
mice
n
per
group
memori
cell
stain
biolegend
fitcantimous
biolegend
peantimous
biolegend
biolegend
memori
cell
stain
percpantimous
biolegend
peantimous
biolegend
pacif
blueantimous
biolegend
antibodi
stain
cell
fix
cytofixcytoperm
becton
dickson
analyz
fac
canto
ii
flow
cytomet
facsdiva
softwar
statist
analys
perform
graphpad
prism
data
three
separ
experi
given
mean
standard
deviat
data
statist
analyz
twotail
independ
student
ttest
spss
level
statist
signific
set
p
gener
vsvbase
vaccin
tripleantigen
fusion
gene
plasmid
amplifi
kong
et
al
clone
vsv
genom
fifth
posit
vsv
antigenom
figur
rvsv
cell
cultur
supernat
harvest
h
post
transfect
purif
cell
infect
rvsv
appear
cytopath
h
postinfect
figur
express
tripleantigen
gene
confirm
antiflag
antibodi
figur
result
indic
success
gener
vsvbase
vaccin
express
mtb
tripleantigen
fusion
given
import
role
cellular
respons
mycobacteria
infect
evalu
cellular
respons
induc
week
final
dna
immun
figur
releas
assay
perform
determin
whether
vaccin
capabl
induc
high
level
antigen
specif
cell
result
reveal
level
secret
immun
mous
spleen
cell
higher
compar
immun
mous
spleen
cell
follow
incub
protein
figur
p
similar
level
secret
bcg
immun
mous
spleen
cell
significantli
elev
antigen
specif
cell
prolifer
also
observ
immun
mice
respons
protein
compar
mice
immun
figur
p
specif
cytotox
lymphocyt
ctl
activ
assess
use
cell
target
cell
strongest
antigenspecif
cytotox
respons
detect
immun
e
ratio
figur
p
investig
degre
protect
immun
mice
intranas
challeng
colonyform
unit
cfu
bcg
bacteri
load
lung
determin
week
postinfect
observ
vaccin
effici
control
bacteri
growth
lower
observ
mock
group
lower
observ
group
figur
p
p
howev
bacteri
load
immun
mice
significantli
differ
observ
bcg
immun
mice
result
show
vaccin
induc
robust
specif
cell
immun
respons
protect
mice
mycobacteria
infect
week
postvaccin
determin
whether
vaccin
induc
longterm
immun
respons
group
balbc
mice
immun
challeng
bacteri
load
mous
lung
evalu
time
consist
result
shown
figur
week
postbacteri
challeng
mice
protect
vaccin
method
result
log
reduct
lung
cfu
compar
observ
mock
control
although
find
significantli
differ
bcg
group
interestingli
investig
time
point
week
postchalleng
reveal
bacteri
load
group
significantli
lower
bcg
group
figur
p
p
suggest
vaccin
may
induc
better
longterm
protect
bacteri
infect
twenti
four
week
challeng
patholog
lung
tissu
analyz
section
normal
mice
examin
reveal
sever
interstiti
pneumonia
inflamm
diffus
granulomalik
respons
follow
bcg
infect
howev
mice
show
much
less
inflamm
intact
alveolar
morpholog
compar
mice
vaccin
bcg
indic
vaccin
allevi
lung
injuri
follow
bcg
challeng
figur
memori
cell
capabl
respond
rapidli
mediat
faster
viral
clearanc
upon
reexposur
antigen
longterm
immun
respons
base
presenc
memori
tcell
examin
determin
protect
mycobacterium
infect
sondel
et
al
mice
immun
week
final
dna
vaccin
splenocyt
isol
quantifi
memori
cell
respons
cell
cell
gate
cell
flow
cytometri
respect
longterm
memori
cell
character
shown
figur
percentag
memori
cell
higher
group
compar
observ
bcg
group
figur
b
p
p
indic
immun
capabl
provid
sustain
cellular
immun
recent
year
immun
live
replicationcompet
vsv
vaccin
shown
effect
method
vaccin
develop
rose
et
al
haglund
et
al
clark
et
al
braxton
et
al
vsv
vector
share
certain
advantag
use
vaccin
deliveri
specif
induc
robust
humor
cellmedi
immun
follow
singl
dose
absenc
addit
adjuv
publicov
et
al
far
tradit
vaccin
requir
repeat
dose
induc
longlast
immun
specif
adjuv
often
need
exampl
twodos
hevsg
vaccin
requir
action
two
adjuv
hydrogel
cpg
oligo
deoxynucleotid
bossart
et
al
gener
immun
respons
howev
hydrogel
alon
typic
induc
respons
appropri
viral
infect
coffman
et
al
steinhagen
et
al
previous
report
nake
dna
plasmid
encod
protein
inocul
four
time
elicit
robust
cellmedi
immun
respons
kong
et
al
studi
show
protect
along
longterm
immun
respons
mycobacteri
infect
mice
effect
achiev
intranas
immun
singledos
vsvbase
vaccin
vaccin
induc
cell
known
secret
phagocyteactiv
type
cytokin
like
contribut
intracellular
antimicrobi
defens
activ
macrophag
kerksiek
pamer
schroder
et
al
recent
studi
suggest
cell
play
critic
role
combat
bacteri
infect
malley
et
al
pilion
harvil
tripl
antigen
fusion
contain
three
mtb
antigen
boesen
et
al
et
al
bett
et
al
cover
high
densiti
cell
epitop
promot
strong
cell
immun
respons
includ
function
cell
subset
secret
millington
et
al
stabli
express
earli
late
stage
mtb
infect
significantli
enhanc
protect
immun
character
high
proport
multifunct
cell
mtb
infect
mice
cynomolgu
macaqu
aagaard
et
al
lin
et
al
strong
cellular
immun
respons
induc
singl
dose
shown
increas
releas
lymphocyt
prolifer
cell
cytotox
figur
although
similar
bacteri
load
measur
bcg
immun
mice
week
postchalleng
becam
significantli
differ
longterm
interv
includ
week
postchalleng
result
differ
report
roedig
roedig
et
al
confer
transient
protecion
pulmonari
mtb
challeng
follow
singl
respiratori
mucos
immun
consid
viral
vector
system
use
possibl
explan
tripleantigen
fusion
robust
induc
antitb
immun
respons
compar
use
singl
mtb
antigen
memori
cell
contribut
host
defens
wide
rang
viral
intracellular
bacteri
infect
harti
et
al
effector
memori
cell
sustain
high
prolif
capac
central
memori
cell
import
potenti
success
tb
vaccin
andersen
woodworth
nunesalv
et
al
lymph
node
home
receptor
downregul
upon
ctl
activ
ottenhoff
kaufmann
surfac
protein
requir
lymphocyt
extravas
inflammatori
site
upregul
repres
marker
memori
cell
harti
et
al
studi
observ
larg
popul
memori
cell
isol
splenocyt
week
postvaccin
although
observ
much
higher
percentag
memori
cell
follow
immun
rel
bcgimmun
mice
unabl
determin
whether
memori
cell
gener
induct
without
antigenspecif
tetram
stain
previous
vsvbase
vaccin
reportedli
induc
poli
function
cell
prolifer
secret
activ
cytokin
contribut
antivir
defens
wu
et
al
howev
studi
shown
capabl
vaccineelicit
cell
secret
multipl
cytokin
infect
develop
longliv
memori
cell
exhibit
enhanc
capabl
control
infect
evidenc
clinic
failur
ottenhoff
kaufmann
conclus
result
indic
vsvbase
tb
vaccin
elicit
robust
cellular
immun
respons
well
memori
cell
respons
protect
vaccin
mice
bcg
infect
longterm
period
time
follow
needlefre
singl
dose
find
show
use
vsv
antigendeliveri
vector
potenti
success
option
tbvaccin
develop
cd
sx
design
studi
mz
perform
experi
mz
cd
sx
interpret
data
mz
cd
sx
wrote
manuscript
author
approv
final
version
paper
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
